Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

pembrolizumab 81Carboplatin 76Cisplatin 60Paclitaxel 59Specimen Handling 56Magnetic Resonance Spectroscopy 56Gemcitabine 48Docetaxel 38Dexamethasone 37Oxaliplatin 34Fluorouracil 34Bevacizumab 34Pemetrexed 33Leucovorin 33Doxorubicin 33Cyclophosphamide 32durvalumab 29Radiotherapy 29Radiation 29Capecitabine 29Rituximab 26Letrozole 25Irinotecan 24Etoposide 24Vincristine 23Nivolumab 23Lenalidomide 22Taxes 21Prednisone 21Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × ravulizumab × 30 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡